ArticleEndocrine connections2025
Tirzepatide safety in type 2 diabetes: a disproportionality analysis of adverse events using the FDA FAERS database.
Zhenpo Zhang et al.PubMed ↗Full text ↗Publisher ↗
No numbers read from the abstract.
2 papers cite it
this papercites it